Parallel Session 11: Complications of Immunotherapy
Agenda

Basic Mechanisms: B Rapoport, Rosebank
Recommendations: M Postow, MSKCC
Emergencies: T Cooksley, Manchester UF
GI Toxicities: M Dougan, MGH
Rheumatologic Toxicities: A Bass, HSS
Conclusion, Q&A: All Faculty
Increasing Approvals and Use of IO

- 2010: FDA approval of ipilimumab for unresectable or metastatic melanoma
- 2011: FDA approval of pembrolizumab for unresectable or metastatic melanoma after ipilimumab or a BRAF inhibitor
- 09/04/14: Pembrolizumab approved for unresectable or metastatic melanoma after ipilimumab or a BRAF inhibitor
- 12/23/14: Blinatumomab approved for Ph-negative pre-B cell ALL
- 12/22/14: Nivolumab approved for unresectable or metastatic melanoma after ipilimumab or a BRAF inhibitor
- 05/17/16: Nivolumab approved for Hodgkin’s lymphoma
- 05/18/16: Atezolizumab approved for mUBC
- 08/05/16: Pembrolizumab approved for mHNSCC
- 10/18/16: Atezolizumab approved for mNSCLC
- 10/24/16: Pembrolizumab approved for 1st line PD-L1+ mNSCLC
- 11/10/16: Nivolumab approved for mINSCC
- 11/21/16: Daratumumab + Lenalidomide + Dexamethasone for multiple myeloma

- 03/04/2017: Avelumab approved for Merkel cell carcinoma

Emens et al, EJC 2017
Immune-related Adverse Events Affect Any Organ, Anytime
Clusters of irAEs: Misery Loves Company

PD-1 inhibitor (n=102)

40%
Immuno-Oncology Subgroup (2019-)

• Create a multidisciplinary team that brings together the best information and ideas
  – Develop educational sessions at MASCC conferences and research projects
  – Resource for information and contacts industry/academia
  – Yearly meeting
Immuno-Oncology Subgroup (2019-)

- Chair: Bernardo L Rapoport, MD
  brapoport@rosebankoncology.co.za

- Vice-Chair: Mario E Lacouture, MD
  lacoutum@mskcc.org
Agenda

Basic Mechanisms: B Rapoport, Rosebank
Recommendations: M Postow, MSKCC
Emergencies: T Cooksley, Manchester UF
GI Toxicities: M Dougan, MGH
Rheumatologic Toxicities: A Bass, HSS
Conclusion, Q&A: All Faculty